Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer

Human epidermal growth factor receptor (HER)2 over-expression is associated with a shortened disease-free interval and poor survival. Although the addition of trastuzumab to chemotherapy in the first-line setting has improved response rates, progression-free survival, and overall survival, response...

Descripción completa

Detalles Bibliográficos
Autores principales: Morrow, Phuong Khanh H, Zambrana, Francisco, Esteva, Francisco J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750101/
https://www.ncbi.nlm.nih.gov/pubmed/19664181
http://dx.doi.org/10.1186/bcr2324

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750101/
https://www.ncbi.nlm.nih.gov/pubmed/19664181
http://dx.doi.org/10.1186/bcr2324

Ejemplares similares